GILD

Gilead Sciences Option Alert: Aug 15 $120 Calls Sweep (77) near the Ask: 5002 vs 8509 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Aug 15 $120 Calls Sweep (77) near the Ask: 5002 @ $1.177 vs 8509 OI; Earnings 8/7 After Close [est] Ref=$111.54

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (5) below Bid!: 1800 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (5) below Bid!: 1800 @ $26.8 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$114.33

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls at the Bid: 1600 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls at the Bid: 1600 @ $27.28 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$114.23

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (53) near the Bid: 380 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (53) near the Bid: 380 @ $27.034 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$114.375

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (10) near the Ask: 444 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (10) near the Ask: 444 @ $26.4 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.11

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (21) near the Ask: 247 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (21) near the Ask: 247 @ $26.4 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.05

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (21) below Bid!: 1000 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (21) below Bid!: 1000 @ $26.051 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.07

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (9) near the Ask: 207 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (9) near the Ask: 207 @ $25.6 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.42

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (4) near the Ask: 198 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (4) near the Ask: 198 @ $25.6 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.515

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (5) near the Ask: 200 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (5) near the Ask: 200 @ $25.6 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.59

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (160) below Bid!: 1335 vs 10295 OI; Earnings 8/7 After Close [est] 

Gilead Sciences Option Alert: Jun, 2027 $97.5 Calls Sweep (160) below Bid!: 1335 @ $25.714 vs 10295 OI; Earnings 8/7 After Close [est] Ref=$113.76

Gilead Sciences (NASDAQ:GILD) Bolsa

GILEAD SCIENCES INC

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Time magazine

Long Ideas

Tech

Media

Trading Ideas

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

TIME revela las 100 empresas más influyentes de 2025. Conoce las compañías en bolsa que lideran innovación y crecimiento este año.

Las empresas más influyentes de 2025 según TIME: ¿Cuáles están en bolsa?

Alphabet

Earnings

News

Pre-Market Outlook

Markets

INTC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: PSX, GOOG, SLB, INTC y GILD.

5 acciones en el foco este viernes: PSX, GOOG, SLB, INTC y GILD

Entertainment

Management

TSLA

Descubre quiénes son los directores ejecutivos elegidos por Time en 2025 y cómo han transformado sus sectores clave.

Elon Musk lidera CEOs influyentes que transformaron industrias según lista Time 2025

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 13.62%. Currently, Gilead Sciences has a market capitalization of $139.43 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 15 years ago, it would be worth $681.19 today based on a price of $112.09 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752532212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo&#xAE;) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, Adolescents and Young People –
– Data Also Showed Twice-Yearly Injectable PrEP was Preferred vs. Daily Oral Medication Among PURPOSE Trial Participants –
– Gilead's Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range of Populations –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo&#xAE;) was effective and well tolerated among a broad range of populations who need or want pre-exposure prophylaxis (PrEP) for HIV prevention, including pregnant and lactating women, adolescents and young people, and supports lenacapavir dosing recommendations for people in special situations, such as those taking medication to treat tuberculosis (TB) and other conditions. Researchers will also present new quantitative and qualitative data showing that participants in both Phase 3 PURPOSE trials indicated a preference for twice-yearly PrEP injections over daily oral medication.
The new data, from the company's pivotal Phase 3 PURPOSE 1 (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04994509%3Fterm%3DNCT04994509%26rank%3D1&amp;esheet=54289692&amp;newsitemid=20250713258800&amp;lan=en-US&amp;anchor=NCT04994509&amp;index=1&amp;md5=bf77265ad9af02d525d66af02ccf43fd">NCT04994509</a>) and PURPOSE 2 (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04925752%3Fcond%3Dhiv%26term%3Dpurpose%25202%26rank%3D1&amp;esheet=54289692&amp;newsitemid=20250713258800&amp;lan=en-US&amp;anchor=NCT04925752&amp;index=2&amp;md5=08341679c763a0deb1c553882148b726">NCT04925752</a>) trials that assessed the efficacy and safety of twice-yearly Yeztugo for PrEP, will be presented via poster sessions and during a Yeztugo-dedicated oral session at the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iasociety.org%2Fconferences%2Fias2025&amp;esheet=54289692&amp;newsitemid=20250713258800&amp;lan=en-US&amp;anchor=International+AIDS+Society+%28IAS%29+2025%2C+the+13th+IAS+Conference+on+HIV+Science&amp;index=3&amp;md5=debde7f02840c13006417b9a31bafa38">International AIDS Society (IAS) 2025, the 13th IAS Conference on HIV Science</a> in Kigali, Rwanda on Thursday, July 17. The data presentations come less than a month after the U.S. Food and Drug Administration (FDA) approved Yeztugo as the first and only twice-yearly HIV prevention option. The data underscore Gilead's focus on intentional inclusion in the PURPOSE program to ensure broad and robust population data at the trials' primary analyses, as well as spotlight the community and organizational collaborations that guided the trial design and implementation process.

Biotech

General

Gilead Presents New Phase 3 Data Showing Twice-Yearly Injectable PrEP Yeztugo Is Effective, Well Tolerated, And Preferred Over Daily Pills Across Diverse Populations, Including Pregnant Women And Adolescents

Gilead Sciences Says Gilead Researchers And Collaborators To Present New Phase 3 PURPOSE Trial Data For HIV Prevention At IAS 2025

Bill Gates has raised concerns over the severe consequences of the U.S. aid cuts on HIV programs in Africa, calling for a reversal of the decision.
What Happened: Gates, a co-founder of Microsoft Corp., highlighted the dire situation unfolding in Africa in a post on X, citing the cuts in U.S. aid. He shared a tweet by Sam Stein, a journalist, who reported on the distressing conditions faced by an HIV doctor in Africa, whose work relies on USAID and PEPFAR.
See Also: <a href="https://benzinga.com/markets/cryptocurrency/24/01/36721989/jim-cramer-bearish-at-40k-unlikely-that-bitcoin-finds-its-footing-cramertracker-replies-le">Jim Cramer Bearish At $40K: &#8216;Unlikely That Bitcoin Finds Its Footing,&#8217; CramerTracker Replies: &#8216;Legend, Thanks Jim!&#8217; &#8211; Benzinga</a>
Gates emphasized that the devastating effects of these cuts are entirely preventable and urged a reversal of the decision.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The devastating effects of these cuts are entirely preventable—and it's not too late to reverse them. <a href="https://t.co/wWBjW842gR">https://t.co/wWBjW842gR</a>
&mdash; Bill Gates (@BillGates) <a href="https://twitter.com/BillGates/status/1943750242148790622?ref_src=twsrc%5Etfw">July 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The U.S. aid cuts have been a point of concern for Gates for some time now. He previously warned that the cuts could lead to a <a href="https://www.benzinga.com/news/health-care/25/07/46260344/bill-gates-warns-us-aid-cuts-could-kill-millions-of-children-end-hiv-programs-leave-75-million-unvaccinated-devastating-lancet-study-gavi-unaids-sound-alarm">catastrophic global health crisis</a>, potentially causing millions of additional deaths by 2040. The aid reductions have already resulted in a significant impact, with studies projecting 8 million additional child deaths before age five by 2040, along with 15.2 million excess AIDS deaths and 2.2 million additional tuberculosis deaths between 2025 and 2040.
The situation is particularly concerning as the U.S. is a major contributor to global health initiatives. Gates&#8217; warnings come at a time when the U.S. is also facing <a href="https://www.benzinga.com/news/health-care/25/06/46159226/bill-gates-warns-us-its-not-too-late-to-change-course-as-trump-team-targets-hiv-funding-cuts">potential cuts</a> to its HIV funding, which could have a significant impact on global health programs.
Despite these challenges, there have been efforts to mitigate the impact of the aid cuts. For instance, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) recently committed to <a href="https://www.benzinga.com/news/health-care/25/07/46325593/gileads-lenacapavir-plan-faces-global-hurdles-as-it-commits-to-no-profit-access-for-2-million">no-profit access</a> for its HIV-1 capsid inhibitor, Lenacapavir, for up to two million people in countries supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria.
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/07/46374193/ethereum-xrp-solana-no-youll-find-exponential-altseason-returns-in-lesser-known-coins-experts-say">Ethereum? XRP? Solana? No, You&#8217;ll Find Exponential Altseason Returns In Lesser-Known Coins, Experts Say &#8211; Benzinga</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Alexandros Michailidis on Shutterstock

Health Care

Bill Gates Warns Of 'Devestating Effects' Of USAID Funding Cuts: 'It's Not Too Late To Reverse Them'

WIIM

Shares of drug stocks are trading lower after the FDA reportedly indicated it could fast track drugs to companies that cut US prices in line with other countries.

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

Equities

ABBV

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead&#8217;s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">pre-exposure prophylaxis (PrEP)</a>.
Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead.
In June, the U.S. Food and Drug Administration (FDA) approved Yeztugo&nbsp;(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46023093/fda-approves-gileads-game-changing-twice-yearly-shot-to-prevent-hiv-transmission-critics-slam-28k-price-tag" rel="noreferrer noopener">people who need or want PrEP</a>.
Yeztugo's annual list price in the U.S. before insurance is $28,218.
A month's supply of Truvada and Descovy, Gilead's daily pills for PreP, are both around $2,000 without insurance, which amounts to around $24,000 per year.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" target="_blank" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a>
The drug was praised as the closest thing to a vaccine and a powerful tool to help control the 45-year-old HIV pandemic. However, advocates and researchers were concerned that the people most affected — especially in low-income countries — might not get access to it, especially after the Trump administration started reducing foreign aid, the STAT news wrote.
In October 2024, Gilead signed non-exclusive, royalty-free voluntary licensing agreements to manufacture and supply high-quality generic versions of lenacapavir in 120 high-incidence, resource-limited countries, primarily low- and lower-middle-<a href="https://www.benzinga.com/pressreleases/25/07/b46316129/gilead-finalizes-agreement-with-the-global-fund-to-accelerate-access-to-twice-yearly-lenacapavir-f" target="_blank" rel="noreferrer noopener">income countries (LLMICs)</a>.
Until licensed generic versions are available and can fully meet demand in LLMICs, Gilead also committed to providing Gilead-supplied lenacapavir for PrEP at no profit.
Under this strategic partnership agreement with the Global Fund, countries supported by the Global Fund that are among the 120 high-incidence, resource-limited countries can access lenacapavir for PrEP.
STAT News <a target="_blank" href="https://www.statnews.com/pharmalot/2025/07/09/hiv-prevention-lenacapavir-yeztugo-gilead-global-fund-distribution/?utm_campaign=rss" rel="noreferrer noopener">writes</a> that the deal does not cover the U.S. government&#8217;s PEPFAR program, which has been the top global supplier of HIV prevention drugs.
In December 2024, PEPFAR said it would work with three other organizations to speed up the drug&#8217;s rollout. However, those plans were disrupted when the Trump administration made major cuts to foreign aid, creating uncertainty around PEPFAR's future and related agreements.
The situation raises lingering questions, especially about the Biden administration's plans for PEPFAR, a key U.S. global health program. Trump's 2026 budget proposal includes a $1.9 billion <a target="_blank" href="https://www.kff.org/global-health-policy/fact-sheet/the-trump-administrations-foreign-aid-review-status-of-pepfar/" rel="noreferrer noopener">cut</a> to the program.
Meanwhile, whether the Global Fund can afford to buy the doses independently is uncertain. Although the group has spent over $65 billion fighting infectious diseases since 2002, it&#8217;s facing funding challenges. PEPFAR has historically been a major source of its budget, and other wealthy nations have also reduced their foreign aid contributions in recent years.
GILD Price Action: GILD stock is up 1.26% at $112.46 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46321038/buckle-up-visa-stablecoins-process-800-billion-in-transactions-per-month-report-finds" target="_blank" rel="noreferrer noopener">Buckle Up, Visa: Stablecoins Process $800 Billion In Transactions Per Month, Report Finds</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Global

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has risen 10.12% since its last report. The company recently reported that it has 22.99 million shares sold short, which is 1.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752073218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Gilead Sciences?

In a rapidly evolving financial landscape, insights from top investment strategists and analysts can significantly influence market sentiment <a href="https://www.benzinga.com/topic/economy">and investment strategies.</a>
On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/08/final-trades-synovus-nextera-energy-gilead-and-the-iyf.html">Halftime Report Final Trades</a>,&#8221; Brian Belski, chief investment strategist at BMO Capital Markets, said Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) has 10 times earnings and 12 <a href="https://www.benzinga.com/quote/SNV/analyst-ratings">times free cash flow</a>.
Supporting his view, Barclays analyst Jared Shaw maintained a Synovus Financial rating of Overweight on Tuesday and raised the price target from $60 to $67.
Shannon Saccocia, CFA, chief investment officer of NB Private Wealth, picked iShares U.S. Financials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYF#NYSE">IYF</a>), saying deregulation is going to be a very significant tailwind for the financial sector.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jenny Van Leeuwen Harrington, chief executive officer of Gilman Hill Asset Management, LLC, named NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) as her final trade.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, picked Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) as his final trade.
According to recent news, Gilead Sciences and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) entered into an exclusive option and license agreement on June 25 to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad potential for oncology treatments.
Price Action:
<ul class="wp-block-list">
<li>Synovus Financial shares gained 0.6% to close at $54.92 on Tuesday.</li>
<li>iShares U.S. Financials ETF fell 0.8% during the session.</li>
<li>NextEra Energy fell 2.3% to settle at $41.69 on Tuesday.</li>
<li>Gilead Sciences shares fell 0.6% to close at $111.06 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a></li>
</ul>
Photo: Gumbariya on Shutterstock.com

iShares Dow Jones US Financial Sector Index Fund

KYMR

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

– Strategic Partnership Agreement is Part of Gilead's Commitment to Provide Lenacapavir at No Profit in High-Incidence, Resource-Limited Countries Until Licensed Generics Can Fully Meet Demand –

Contracts

Gilead Joins Strategic Partnership With Global Fund To Accelerate Access To Twice-Yearly Lenacapavir For HIV Prevention For Up To 2M People

Analyst Ratings

NEEPR

CNBC Halftime Report Final Trades: Synovus Financial, iShares U.S. Financial ETF, Gilead Sciences; NextEra Energy, Inc. 6.926% Corporate Units

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">EXCLUSIVE: June&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do CoreWeave, Nvidia, Apple Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending July 4:
US Foods Holding Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>): The food service distributor saw increased interest from readers during the shortened holiday week. JPMorgan maintained a Neutral rating on the stock while <a href="https://www.benzinga.com/quote/USFD/analyst-ratings">raising the price target </a>from $82 to $85. US Foods shares trade near all time highs with momentum coming from the earnings report <a href="https://www.benzinga.com/25/05/45297979/whats-going-on-with-us-foods-stock-on-thursday">back in May.</a> The company missed Street estimates for earnings per share and revenue, while reporting a 4.5% year-over-year sales increase and increased gross profits and total case volume. The company's net income was up 40% year-over-year in the first quarter. After a strong quarterly report and a June defense agency contract award win, the company could be one to watch.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="999" height="497" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486.png" alt="" class="wp-image-972632" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165727/Screenshot-486-768x382.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>): Interest has been rising in gold and precious metals stocks in recent weeks. This week's Stock Whisper Index sees a precious metals company make it, but one of a different nature. Unlike past stocks that mine the metals that have made the list, Franco-Nevada is a gold-focused royalty and streaming company. The company does not operate mines or conduct exploration, instead owning a portfolio of royalties and streams. Franco-Nevada has a history of increasing its dividend and could be viewed as a safer bet in the sector than some of the other companies. UBS maintained a Buy rating and <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">raised the price target</a> from $205 to $210.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="997" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487.png" alt="" class="wp-image-972633" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165742/Screenshot-487-768x382.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Johnson Controls International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>): The commercial HVAC and building management company saw strong interest from readers during the week, which comes with analysts increasing their price target on the stock in recent months. Johnson Controls shares recently hit new all time highs with the stock up 35% year-to-date in 2025. Investors could be getting ready for upcoming third-quarter financial results, which are expected in late July. The company has beaten analyst estimates for earnings per share and revenue in two straight quarters. The strong recent earnings momentum along with an increased share buyback plan could see shares continue to take out new highs.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="995" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488.png" alt="" class="wp-image-972634" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165757/Screenshot-488-768x390.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>): One of the largest defense contractors, Northrop Grumman saw increased interest from readers during the week with tensions in the Middle East<a href="https://www.benzinga.com/markets/equities/25/06/46045651/northrop-grumman-jumps-5-overnight-as-b-2-bombers-return-to-missouri-after-36-hour-iran-strike-trump-says-job-well-done"> remaining heightened.</a> The company manufactures the B2 bomber and is involved in several other top defense weapons used. Investors are likely anticipating the company's second-quarter financial results later this month with analysts forecasting earnings per share to grow to $6.70 and revenue to decline to $10.11 billion. The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters and for revenue in seven of the last 10 quarters. Northrop Grumman could be a winner if tension escalates in the Middle East and potentially thanks to increased defense spending by the US and other nations.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="999" height="503" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489.png" alt="" class="wp-image-972635" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165811/Screenshot-489-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): The biotech best known for its work on HIV and Hepatitis drugs recently<a href="https://www.benzinga.com/news/fda/25/06/46023093/fda-approves-gileads-game-changing-twice-yearly-shot-to-prevent-hiv-transmission-critics-slam-28k-price-tag"> received FDA approval</a> for Yeztugo, the first and only twice-yearly option in the US for pre-exposure prophylaxis to reduce the risk of HIV in adults. While the company received approval there are questions over how much the drug will be priced at with Gilead working with insurers to increase coverage options. High pricing of the drug could cause pushback against the company, while also helping boost revenue and earnings. Gilead is set to report quarterly financial results in August and could provide an update on the drug. The company has beaten analyst estimates in five straight quarters and beaten analyst revenue estimates in nine of the last 10 quarters.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="1001" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490.png" alt="" class="wp-image-972636" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03165827/Screenshot-490-768x379.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45827517/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-68" target="_blank" rel="noreferrer noopener">June 6</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45938888/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-69" target="_blank" rel="noreferrer noopener">June 13</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46043300/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-70" target="_blank" rel="noreferrer noopener">June 20</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46157351/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-71">June 27</a></li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46236448/exclusive-2025s-first-half-most-searched-tickers-on-benzinga-pro-where-do-nvidia-tesla-apple-stock-rank">EXCLUSIVE: 2025&#8217;s First Half Most-Searched Tickers On Benzinga Pro — Where Do Nvidia, Tesla, Apple Stock Rank?</a></li>
</ul>

Exclusives

USFD

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.67% on an annualized basis producing an average annual return of 12.17%. Currently, Gilead Sciences has a market capitalization of $138.95 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751584511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today

The U.S. Food and Drug Administration (FDA) announced on Friday that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">CAR T cell immunotherapies</a>.&nbsp;
These products are gene therapies currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma.
&#8220;The FDA has taken the bold step to remove the Risk Evaluation and Mitigation Strategy requirement from giving CAR T therapies. REMS is a useful safety system, but reevaluation over time helps inform whether a REMS is still needed to ensure that the benefits of a product outweigh its risks,&#8221;&nbsp;said FDA Vinay Prasad, Chief Medical and Scientific Officer and Director, Center for Biologics Evaluation and Research.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46144447/fda-eases-rules-for-bristol-myers-cell-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Rules For Bristol Myers&#8217; Cell Therapies For Blood Cancers</a>
&#8220;Eliminating the REMS that is no longer needed also expedites the delivery of potentially curative treatments to patients and reduces the burden on providers,&#8221; he added.
A REMS is a safety <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">program</a> that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.
The FDA determined that the approved REMS for the f<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se" rel="noreferrer noopener">ollowing products should be eliminated</a> because a REMS is no longer necessary to ensure that the benefits of the autologous CAR T cell immunotherapies outweigh their risks.&nbsp;
The products affected by this change include Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Carvykti (ciltacabtagene autoleucel), Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah (tisagenlecleucel), and Gilead Science Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).
The elimination of REMS for the above products removes the requirements that hospitals and their associated clinics that dispense products must be specially certified and have on-site, immediate access to tocilizumab.
&#8220;Continuous monitoring and assessment of the safety of all biological products, including the CAR T cell immunotherapies, is an FDA priority and we remain committed to informing the public when we learn new information about these products,&#8221; the FDA said in a press release.
As per a <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">safety</a> statement on Thursday, the regulator also reduced its requirement that patients remain near the facility where they received treatment to two weeks. The agency also removed its advice to patients to avoid driving for two weeks following product administration.
Commenting on the development and accessibility of CAR T-cell therapies, William Blair said, &#8220;Overall, we view the removal of the REMS program for CAR-T cell therapies as a positive development for the space, as it supports the notion that the FDA is working to minimize red tape and increase access to potentially curative treatments for patients. We also believe the removal of the REMS requirements could increase access and use of these therapies in the community settings.&#8221;
Analyst Sami Corwin said the update also suggests there will likely be no REMS requirements for CD19 and BCMA autologous CAR-T cell therapies approved in the future, such as Arcellx, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) anito-cel.
Moreover, Corwin highlighted the positive implications for companies developing CAR T-cell therapies for autoimmune diseases, such as Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), Bristol-Myers, and Cabaletta Bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>), &#8220;given that the safety profile is more tolerable than in oncology.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46163176/microsoft-stock-could-soar-44-on-ai-boom-analyst-says-but-theres-a-catch" target="_blank" rel="noreferrer noopener">Microsoft Stock Could Soar 44% On AI Boom, Analyst Says — But There&#8217;s A Catch</a></li>
</ul>
Photo by Tada Images via Shutterstock

ACLX

AUTL

CABA

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers

Time Magazine&#8217;s annual 100 Most Influential Companies list for 2025 includes many companies investors are familiar with, with numerous names originating from the growing <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector.</a>
The <a href="https://time.com/7297630/time-reveals-the-2025-time100-most-influential-companies-in-the-world/">list</a> seeks to honor the top businesses that are helping "chart an essential path forward."
"No single data point or financial metric makes a TIME100 Company. Instead, we looked at a mosaic of qualities, studying impact, innovation, ambition, and success, each in the forms that take shape today. And as we say for all TIME100 projects: influence comes in many forms, for better and for worse," Time editors said of the list.
 The Public Companies: Similar to the list of the <a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Most Influential People</a> that Time published earlier this year, the list of influential companies includes top tech, AI, crypto, and healthcare names that are experiencing impressive growth and bringing life-changing technology to consumers or other companies.
Here is the list of publicly traded companies or those that are part of a publicly traded company. It is broken down by the key groups used by Time: Innovators, Disruptors, Leaders, Titans and Pioneers.
Innovators
<ul class="wp-block-list">
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>): footwear</li>
<li>Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>): Chinese e-commerce</li>
<li>Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>): video games</li>
<li>BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>): electric vehicles</li>
<li>Gap, unit of Gap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>): apparel</li>
<li>Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>): sports and outdoor retailer</li>
<li>EssilorLuxottica (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESLOY#OTC">ESLOY</a>): sunglasses, optical wear</li>
</ul>
Disruptors
<ul class="wp-block-list">
<li>Waymo, unit of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Life Time Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>): fitness centers</li>
<li>Elf Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>): beauty products</li>
<li>Poppi, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): beverages</li>
<li>UFC, unit of TKO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>): fighting sports league</li>
<li>Pop Mart (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PMRTY#OTC">PMRTY</a>): pop culture retailer</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): cryptocurrency trading platform</li>
<li>SharkNinja Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>): home appliances</li>
</ul>
Leaders
<ul class="wp-block-list">
<li>Engie (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ENGIY#OTC">ENGIY</a>): energy company</li>
<li>Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>): industrial and logistics real estate</li>
<li>Cloudflare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NET#NASDAQ">NET</a>): a software company</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): biotechnology, healthcare</li>
<li>Duolingo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): mobile learning</li>
<li>BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): financials</li>
<li>Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>): automotives</li>
<li>LinkedIn, unit of Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): social networking</li>
<li>Coursera Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>): online learning</li>
</ul>
Titans
<ul class="wp-block-list">
<li>Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): conglomerate</li>
<li>Comcast, NBC Universal, units of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): media and entertainment</li>
<li>L'Oreal (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LRLCY#OTC">LRLCY</a>): beauty company</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): food delivery</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): social networking</li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>): a software company</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): e-commerce</li>
<li>Arm Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>): semiconductors</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): consumer products</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): financial technology</li>
<li>MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>): Latin American e-commerce</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): retailer</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): streaming</li>
<li>Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>): semiconductors</li>
<li>Universal Music Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UNVGY#OTC">UNVGY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>): music publishing</li>
</ul>
Pioneers
<ul class="wp-block-list">
<li>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>): semiconductors</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>): oil and gas</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): medical devices</li>
<li>Softbank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>): telecom and e-commerce conglomerate</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): gene editing</li>
</ul>
Read Also: <a href="https://www.benzinga.com/general/social-media/24/09/40760039/elon-musk-less-influential-to-artificial-intelligence-than-scarlett-johansson-time-magazine-">Elon Musk Less Influential To Artificial Intelligence Than Scarlett Johansson, Time Magazine Says: Billionaire Brushes Off Exclusion – &#8216;Magazines Do Not Establish Relevance, History Does&#8217;</a>
Why It's Important: Nearly half of this year's list includes companies that are publicly traded or part of publicly traded companies. This means investors can get exposure to what Time considers some of the most influential companies in the world.
Some of the companies are newer to the public market, which could mean that the 50+ companies that are not yet public could be among IPOs to watch for in the second half of 2025 and beyond.
Some of the most recognizable private companies on this year's list include OpenAI, Polymarket, Anthropic, Anduril, Beast Industries and SpaceX.
When seeking companies that can drive revenue growth and gain customer and consumer adoption, the most influential lists can be a valuable starting point for investors.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44367926/mark-cuban-kevin-oleary-rejected-poppi-on-shark-tank-pepsi-just-paid-1-9-billion-to-acquire-company">Mark Cuban, Kevin O&#8217;Leary Rejected Poppi On Shark Tank, Pepsi Just Paid $1.9 Billion To Acquire Company</a></li>
</ul>
Photo: Shutterstock

44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$103.00</td>
<td>$76.5K</td>
<td>1.3K</td>
<td>6.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$110.00</td>
<td>$98.1K</td>
<td>12</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$28.4K</td>
<td>4.0K</td>
<td>707</td>
</tr>
<tr>
<td>SMLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>161</td>
<td>657</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we observe a put option sweep with bearish sentiment. It expires in 2 day(s) on June 27, 2025. Parties traded 494 contract(s) at a $103.00 strike. This particular put needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $76.5K, with a price of $155.0 per contract. There were 1365 open contracts at this strike prior to today, and today 6023 contract(s) were bought and sold. 
• Regarding VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 51 day(s) on August 15, 2025. Parties traded 249 contract(s) at a $110.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $98.1K, with a price of $389.0 per contract. There were 12 open contracts at this strike prior to today, and today 1001 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option sweep with bullish sentiment. It expires in 51 day(s) on August 15, 2025. Parties traded 200 contract(s) at a $30.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.4K, with a price of $142.0 per contract. There were 4078 open contracts at this strike prior to today, and today 707 contract(s) were bought and sold. 
• Regarding SMLR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), we observe a call option sweep with neutral sentiment. It expires in 86 day(s) on September 19, 2025. Parties traded 34 contract(s) at a $40.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $760.0 per contract. There were 161 open contracts at this strike prior to today, and today 657 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SMLR

VRNA

4 Health Care Stocks With Whale Alerts In Today's Session

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">oncology treatment potential</a>.
CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
Kymera can receive up to $750 million in total payments, including up to $85 million in upfront and potential <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46091245/gilead-sciences-and-kymera-therapeutics-enter-into-exclusive-option-and-license-agreement-to-devel" rel="noreferrer noopener">option exercise payments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
In addition, Kymera may receive tiered royalties ranging from the high single-digits to the mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program.
If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration.
The transaction with Kymera is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by approximately $0.02-$0.03.
The core of this collaboration lies in the innovative approach of MGDs. Unlike traditional inhibitors that merely block the function of disease-driving proteins, MGDs work by selectively eliminating these proteins.
As Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences, stated, this mechanism &#8220;aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue.&#8221;
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, highlighted that their &#8220;highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile.&#8221;
Concurrently, Kymera Therapeutics announced an update on its IRAK4 partnership with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent, and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46091325/kymera-therapeutics-announces-sanofi-irak4-collaboration-update" rel="noreferrer noopener">into clinical studies</a>.
Following preclinical work supporting its development potential, KT-485 is being prioritized for development under the companies&#8217; existing IRAK4 collaboration and is expected to advance into Phase 1 testing next year.
Based on the planned development of KT-485, Sanofi <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30076238/kymera-therapeutics-stock-jumps-after-positive-data-from-atopic-dermatitis-trial" rel="noreferrer noopener">will not advance KT-474</a>.
Sanofi was conducting Phase 2 trials for hidradenitis suppurativa and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39675035/kymera-announces-expansion-of-kt-474-sar444656-hs-and-ad-phase-2-studies-following-interim-review-" rel="noreferrer noopener">atopic dermatitis indications</a>.
In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the companies&#8217; collaboration agreement terms.
Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.
Kymera can receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
Price Action: SNY stock is down 0.76% at $48.05, KYMR stock is down 4.54% at $45, and GILD stock is down 0.28% at $106.90 during the premarket session at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46093513/sam-altman-crushes-openai-microsoft-feud-rumors-hails-really-wonderfully-good-bond-with-satya-nadella" target="_blank" rel="noreferrer noopener">Sam Altman Crushes OpenAI-Microsoft Feud Rumors, Hails &#8216;Really Wonderfully Good&#8217; Bond With Satya Nadella</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Movers

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Gilead Sciences And Kymera Enter Into Exclusive Option And License Agreement To Accelerate Development And Commercialization Of MGD Program Targeting CDK2 With Broad Oncology Treatment Potential Including In Breast Cancer And Other Solid Tumors

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.59% on an annualized basis producing an average annual return of 12.01%. Currently, Gilead Sciences has a market capitalization of $132.09 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,798.39 today based on a price of $106.19 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750713324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yeztugo&nbsp;(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">who need or want PrEP</a>.
Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative. 
The first PrEP medication, which was also developed by Gilead, was approved in the <a href="https://www.benzinga.com/pressreleases/25/06/b46004872/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months" target="_blank" rel="noreferrer noopener">U.S. in 2012</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45982235/gileads-hiv-prevention-drug-could-be-manufactured-at-shocking-low-cost-report" rel="noreferrer noopener">Gilead&#8217;s HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report</a>
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Ffull-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+1+trial&amp;index=4&amp;md5=75b8ce4877adca4271276392d97406cf" rel="noreferrer noopener">PURPOSE 1 trial</a>, data at the primary analysis showed twice-yearly subcutaneous Yeztugo demonstrated zero HIV infections among 2,134 participants in the Yeztugo group, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada&nbsp;(emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF)&nbsp;in cisgender women in sub-Saharan Africa.
In the&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Fgilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow&amp;esheet=54257682&amp;newsitemid=20250520465880&amp;lan=en-US&amp;anchor=PURPOSE+2+trial&amp;index=6&amp;md5=9249be8d81ad64a52dab27c8a0a16b25" rel="noreferrer noopener">PURPOSE 2 trial</a>, there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous Yeztugo group, demonstrating 99.9% of participants in the Yeztugo group did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral Truvada.
In both trials, Yeztugo, the company&#8217;s injectable HIV-1 capsid inhibitor, also demonstrated superiority in the prevention of HIV infections when compared with background HIV incidence (bHIV)&nbsp;and was generally well-tolerated, with no significant or <a target="_blank" href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" rel="noreferrer noopener">new safety concerns identified</a>.&nbsp;
In the U.S., Gilead is working closely with insurers, healthcare systems and other payers to ensure broad insurance coverage for Yeztugo. Additionally, for eligible commercially insured individuals with commercial insurance, Gilead&#8217;s Advancing Access&nbsp;Co-Pay Savings Program will reduce out-of-pocket costs to as little as zero dollars.
Gilead has submitted a marketing authorization application (MAA) and EU-Medicines for all (EU-M4all) applications with the European Medicines Agency (EMA),&nbsp;both of which the EMA has validated&nbsp;and will review under an accelerated assessment timeline.
Gilead has also filed for regulatory approval for twice-yearly lenacapavir for PrEP with authorities in Australia,&nbsp;Brazil, Canada, and&nbsp;South Africa.
<h2 class="wp-block-heading">Pricing</h2>
Citing an <a target="_blank" href="https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html" rel="noreferrer noopener">email</a> from a Gilead spokesperson, CNBC noted that Yeztugo&#8217;s annual list price in the U.S. before insurance is $28,218.
A month&#8217;s supply of Truvada and Descovy, Gilead&#8217;s daily pills for PreP, are both around $2,000 without insurance, which amounts to around $24,000 per year.
One dose of GSK Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Apretude, which is taken once monthly for the first two months and then once every other month thereafter, costs <a target="_blank" href="https://viivuspricing.com/apretude.html" rel="noreferrer noopener">roughly $4,000</a> before insurance.
Winnie Byanyima, Executive Director of UNAIDS and United Nations Undersecretary-General, <a href="https://www.eatg.org/hiv-news/unaids-urges-gilead-to-drop-price-of-new-hiv-prevention-shot/" target="_blank" rel="noreferrer noopener">said</a>, &#8220;Lenacapavir could be the tool we need to bring new infections under control, but only if it is priced affordably and made available to everyone who could benefit.&#8221;
&#8220;UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of rollout. It is beyond comprehension how Gilead can justify a price of $28,218. If this game-changing medicine remains unaffordable, it will change nothing&#8230;,&#8221; Byanyima added.
AIDS Healthcare Foundation President Michael Weinstein sharply criticized Gilead&#8217;s outrageous pricing, <a target="_blank" href="https://www.businesswire.com/news/home/20250618031796/en/AHF-Gileads-Greed-Kills-Promise-of-Lenacapavir-for-HIV-Prevention" rel="noreferrer noopener">saying</a>, &#8220;What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead&#8217;s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV.&#8221;
Price Action: GILD stock is trading higher by 1.16% to $109.25 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44284430/merck-plans-regulatory-submission-for-two-drug-regime-for-hiv-infection-by-mid-2025" target="_blank" rel="noreferrer noopener">Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025</a></li>
</ul>
Photo by Tada Images via Shutterstock

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

Legal

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Comments

Gilead Sciences

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
10:25 AMJul 11, 2025	CALL	$120.00	Aug 15, 2025	30	5104	5002	60	8509	SWEEP	BULLISH
11:04 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	8887	1800	86	10295	SWEEP	BEARISH
10:36 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	6499	1600	63	10295	TRADE	BEARISH
10:36 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	4885	380	47	10295	SWEEP	BEARISH
09:53 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	4248	444	41	10295	SWEEP	BULLISH
09:53 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	3804	247	37	10295	SWEEP	BULLISH
09:52 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	3409	1000	33	10295	SWEEP	BEARISH
09:51 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	2347	207	23	10295	SWEEP	BULLISH
09:51 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	1923	198	19	10295	SWEEP	BULLISH
09:51 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	1723	200	17	10295	SWEEP	BULLISH
09:51 AMJul 10, 2025	CALL	$97.50	Jun 17, 2027	701	1335	1335	13	10295	SWEEP	BEARISH